临床与组织学预后评分对ANCA相关血管炎肾脏存活的表现
这项回顾性队列研究纳入101例经活检诊断肾脏受累且随访≥12个月的ANCA相关血管炎患者,评估各组织学分型与预后评分对肾脏衰竭的预测效能。中位随访75个月期间37例进展至肾脏衰竭,AKRiS的Harrell C统计量最高(0.817),其预测效能随随访时间延长而下降,加入治疗后峰值eGFR可改善各随访间期的表现。
要点
- 101例ANCA相关血管炎肾脏受累患者中37例在中位75个月随访期间进展至肾脏衰竭。
- AKRiS对肾脏衰竭进展的区分度最佳,Harrell C统计量为0.817(0.749-0.885)。
- AKRiS预测效能随随访间期延长而下降,加入治疗后峰值eGFR可改善各间期表现。
核心结论
- 新型AKRiS可增强对肾脏受累ANCA相关血管炎患者肾脏衰竭的预测。
- 由于AKRiS的预后效能随时间下降,纳入治疗后肾功能的第二次AKRiS计算可能改善其长期表现。
研究设计与样本
- 回顾性队列研究,纳入101例经活检诊断肾脏受累且随访≥12个月的ANCA相关血管炎患者,主要结局为至肾脏衰竭的时间。
主要发现
- 101例患者中37例在中位随访75个月(IQR 39-123)期间进展至肾脏衰竭。
- EUVAS/Berden分型的Harrell C统计量为0.702(0.620-0.784),Mayo Clinic慢性度评分为0.606(0.473-0.738),ANCA新月体百分比评分(PACS)为0.801(0.736-0.867),ANCA肾脏风险评分(ARRS)为0.782(0.706-0.858),改进的ANCA肾脏风险评分(AKRiS)为0.817(0.749-0.885)。
- AKRiS在各亚组间对肾脏衰竭进展风险的区分度最佳。
- AKRiS的预测效能随随访间期延长而下降,加入治疗后达到的峰值估算肾小球滤过率可改善AKRiS在所有随访间期的表现。
- 在随访第一年后进展的病例中,71%由肾脏复发促发肾脏衰竭。
关键数值与推荐
- EUVAS/Berden分型的Harrell C统计量为0.702(0.620-0.784)。
- Mayo Clinic慢性度评分的Harrell C统计量为0.606(0.473-0.738)。
- ANCA新月体百分比评分(PACS)的Harrell C统计量为0.801(0.736-0.867)。
- ANCA肾脏风险评分(ARRS)的Harrell C统计量为0.782(0.706-0.858)。
- 改进的ANCA肾脏风险评分(AKRiS)的Harrell C统计量为0.817(0.749-0.885)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Integrating clinical and histological parameters into prognostic scores may enhance the prediction of progression to kidney failure in anti-neutrophil cytoplasm antibodies-associated vasculitis (AAV). This study aimed to evaluate the prognostic performance of histological classifications and scoring systems for kidney survival in AAV. METHODS: This retrospective cohort study included 101 AAV patients with kidney involvement diagnosed by biopsy and followed for ≥12 months. The main outcome was the time to kidney failure. The prognostic performance of each histological and prognostic score was evaluated using Harrell's C statistic and Akaike's Information Criteria. RESULTS: Among the 101 patients, 37 progressed to kidney failure over a median follow-up of 75 months (IQR 39-123). The Harrell's C statistic was 0.702 (0.620-0.784), 0.606 (0.473-0.738), 0.801 (0.736-0.867), 0.782 (0.706-0.858) and 0.817 (0.749-0.885) for the EUVAS/Berden classification, Mayo Clinic Chronicity Score, Percentage of ANCA Crescentic Score (PACS), ANCA renal risk score (ARRS), and the improved ANCA kidney risk score (AKRiS), respectively. The AKRiS best discriminated the risk of kidney failure progression among subgroups. The AKRiS performance decreased with longer follow-up intervals. Adding the peak estimated glomerular filtration rate attained post-therapy improved the AKRiS performance at all follow-up intervals. Kidney relapses precipitated kidney failure in 71% of cases that progressed after the first year of follow-up. CONCLUSION: The novel AKRiS enhances the prediction of kidney failure in AAV with kidney involvement. As the prognostic yield of AKRiS decreases over time, a second calculation of AKRiS, including post-therapy kidney function, may improve its long-term performance.
引用
- Sandino-Bermúdez MJ, Hernández-Andrade A, Hinojosa-Azaola A, et al. Performance of clinical and histological prognostic scores for kidney survival in ANCA-associated vasculitis. Rheumatology (Oxford). 2025. PMID: 38876974. doi:10.1093/rheumatology/keae336
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。